References
- SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
- SEER Cancer Statistics Review [webpage on the Internet]Previous Version: SEER Cancer Statistics Review, 1975–20102015 Available from: http://seer.cancer.gov/archive/csr/1975_2010/Accessed October 4, 2015
- HungerSPLuXDevidasMImproved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology groupJ Clin Oncol201230141663166922412151
- StockWJohnsonJLStoneRMDose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Cancer20131191909822744771
- ThomasDAO’BrienSFaderlSChemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaJ Clin Oncol201028243880388920660823
- StillerCAChessellsJMFitchettMNeurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG studyBr J Cancer19947059699727947106
- StrevensMJLilleymanJSWilliamsRBShwachman’s syndrome and acute lymphoblastic leukaemiaBr Med J19782612918277273
- PassargeEBloom’s syndrome: the German experienceAnn Genet1991343–41791971809225
- TaylorAMMetcalfeJAThickJMakYFLeukemia and lymphoma in ataxia telangiectasiaBlood19968724234388555463
- De JongeRTissingWJEHooijbergJHPolymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemiaBlood2009113102284228919020309
- PrestonDLKusumiSTomonagaMCancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987Radiat Res19941372 supplS68S978127953
- ErratumRadiat Res19941391129
- GreavesMInfection, immune responses and the aetiology of childhood leukaemiaNat Rev Cancer20066319320316467884
- CampoESwerdlowSHHarrisNLPileriSSteinHJaffeESThe 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsBlood2011117195019503221300984
- HoelzerDThielELöfflerHPrognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adultsBlood19887111231313422030
- WetzlerMDodgeRKMrózekKProspective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experienceBlood199993113983399310339508
- HoelzerDPersonalized medicine in adult acute lymphoblastic leukemiaHaematologica2015100785585826130512
- CampanaDMinimal residual disease in acute lymphoblastic leukemiaHematol Hematology Am Soc Hematol Educ Program2010201071221239764
- BassanRSpinelliOOldaniEImproved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)Blood2009113184153416219141862
- LarsonRADodgeRKBurnsCPA five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811Blood1995858202520377718875
- LinkerCALevittLJO’DonnellMFormanSJRiesCATreatment of adult acute lymphoblastic leukemia with intensive cyclical chemo-therapy: a follow-up reportBlood19917811281428221835410
- KantarjianHThomasDO’BrienSLong-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemiaCancer2004101122788280115481055
- SiveJIBuckGFieldingAOutcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trialBr J Haematol2012157446347122409379
- HuguetFLeguayTRaffouxEPediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 studyJ Clin Oncol200927691191819124805
- BleyerWAPoplackDGProphylaxis and treatment of leukemia in the central nervous system and other sanctuariesSemin Oncol19851221311483892694
- CortesJO’BrienSMPierceSKeatingMJFreireichEJKantarjianHMThe value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemiaBlood1995866209120977662956
- GökbugetNKnebaMRaffTGerman Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaAdult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapiesBlood201212091868187622442346
- LitzowMRFinally moving forward in adult ALLBlood2015125162453245425883226
- GuptaVRichardsSRoweJAcute Leukemia Stem Cell Transplantation Trialists’ Collaborative Group. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysisBlood2013121233935023165481
- FieldingAKRichardsSMChopraRMedical Research Council of the United Kingdom Adult ALL Working PartyEastern Cooperative Oncology GroupOutcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyBlood2007109394495017032921
- GökbugetNStanzeDBeckJGerman Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaOutcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationBlood20121202032204122493293
- TavernierEBoironJMHuguetFGET-LALA GroupSwiss Group for Clinical Cancer Research SAKKAustralasian Leukaemia and Lymphoma GroupOutcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trialLeukemia2007211907191417611565
- KantarjianHGandhiVCortesJPhase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemiaBlood200310272379238612791647
- AbbiKKSRybkaWEhmannWCClaxtonDFPhase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemiaClin Lymphoma Myeloma Leuk2015151414625085441
- Le JeuneCThomasXAntibody-based therapies in B-cell lineage acute lymphoblastic leukaemiaEur J Haematol2015949910824981395
- GruppSAKalosMBarrettDChimeric antigen receptor-modified T cells for acute lymphoid leukemiaN Engl J Med2013368161509151823527958
- KantarjianHThomasDWayneASO’BrienSMonoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemiaJ Clin Oncol201230313876388322891271
- AiJAdvaniACurrent status of antibody therapy in ALLBr J Haematol2015168447148025382151
- RaponiSDe ProprisMSIntoppaSFlow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 casesLeuk Lymphoma20115261098110721348573
- FujimotoMPoeJCInaokiMTedderTFCD19 regulates B lymphocyte responses to transmembrane signalsSemin Immunol19981042672779695183
- BarachoGVMileticAVOmoriSACatoMHRickertRCEmergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiationCurr Opin Immunol201123217818321277760
- DreierTLorenczewskiGBrandlCExtremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibodyInt J Cancer2002100669069712209608
- NagorsenDKuferPBaeuerlePABargouRBlinatumomab: a historical perspectivePharmacol Ther2012136333434222940266
- NagorsenDBaeuerlePAImmunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomabExp Cell Res201131791255126021419116
- OffnerSHofmeisterRRomaniukAKuferPBaeuerlePAInduction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cellsMol Immunol200643676377116360021
- Blincyto® (blinatumomab) Available from: http://pi.amgen.com/united_states/blincyto/blincyto_pi_hcp_english.pdfAccessed October 11, 2015
- WuBHijaziYWolfABrandlCSunYNZhuMPharmacokinetics (PK) of blinatumomab and its clinical implicationsJ Clin Oncol20133115 abstract 3048
- KaplanJBGrischenkoMGilesFJBlinatumomab for the treatment of acute lymphoblastic leukemiaInvest New Drugs20153361271127926383529
- BargouRLeoEZugmaierGTumor regression in cancer patients by very low doses of a T cell-engaging antibodyScience2008321589197497718703743
- KlingerMBrandlCZugmaierGImmunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomabBlood2012119266226623322592608
- ToppMSKuferPGökbugetNTargeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalJ Clin Oncol201129182493249821576633
- ToppMSGökbugetNZugmaierGLong-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLBlood2012120265185518723024237
- GökbugetNDombretHBonifacioMBLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL)Poster presented at: American Society of Hematology (ASH) Annual MeetingDecember 6–9, 2014San Franscisco, CA Abstract 379
- ToppMSGökbugetNZugmaierGPhase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemiaJ Clin Oncol201432364134414025385737
- ToppMSGökbugetNSteinASSafety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyLancet Oncol2015161576625524800
- SchlegelPLangPZugmaierGPediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomabHaematologica20149971212121924727818
- RiberaJ-MFerrerARiberaJGenescàEProfile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemiaOnco Targets Ther201581567157426170691
- BarrettDMTeacheyDTGruppSAToxicity management for patients receiving novel T-cell engaging therapiesCurr Opin Pediatr2014261434924362408
- TeacheyDTRheingoldSRMaudeSLCytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyBlood2013121265154515723678006
- MartinelliGDombretHChevallierPComplete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTARA)Blood2015126issue 23 abstract 679
- MaudeSLFreyNShawPAChimeric antigen receptor T cells for sustained remissions in leukemiaN Engl J Med2014371161507151725317870